Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Zai Lab stock (ZLAB)

Buy Zai Lab stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Zai Lab is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $31.18 – a decrease of 2.56% over the previous week. Zai Lab employs 1,869 staff and has a trailing 12-month revenue of around $399 million.

Our top picks for where to buy Zai Lab stock

Top pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you open and fund a new account within 30 days
  • Access to a financial planner
Customer must fund their Active Invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $1,000 is 0.028%. See full terms and conditions.

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, futures and options with as little as $1
  • After-hours trading available
  • Earn 4% interest on uninvested cash with Gold
  • 24/7 customer support

Top pick for advanced trading tools

Go to site
  • Trade stocks, options, futures, currencies, crypto, precious metals and more
  • Mobile, browser and desktop trading platforms
  • Earn 3.83% APY on your uninvested cash

How to buy Zai Lab stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ZLAB. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Zai Lab stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Product Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Offer
SoFi Wealth Management logo
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.01%
Get up to $1,000 in stock when you open and fund a new account. T&C apply.
Trade stocks, ETFs, and options with zero commissions, invest in IPOs or automate your portfolio, with exclusive perks available through SoFi Plus.
Robinhood logo
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures
$0
$0
4%
Get a free stock when you successfully sign up and link your bank account.
Trade stocks, options, crypto and more, with advanced trading tools, fractional shares and exclusive perks for Gold members.
Interactive Brokers logo
Finder score
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex, Treasury Bills, Precious metals
$0
$0
3.83% Lite
4.83% Pro
Trade a wide range of assets, with global market access and pro-grade trading tools.
OPTO logo
Finder score
Stocks, ETFs
$0
$0
4%
Earn up to $300 when you deposit between $2,000–$25,000+.
Copy top-performing portfolios or build your own stock index on Opto's AI-driven thematic investing platform, and get 4% APY on your cash.
JPMorgan logo
Finder score
Mutual funds, ETFs
$0
$25,000
N/A
Get ongoing access to an advisory team with personalized financial planning and expert-built portfolios. Provider terms & conditions apply
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Zai Lab stock price (NASDAQ: ZLAB)

Use our graph to track the performance of ZLAB stocks over time.

Zai Lab shares at a glance

Information last updated 2025-05-02.
Latest market close$31.18
52-week range$16.01 - $39.77
50-day moving average $33.55
200-day moving average $26.73
Wall St. target price$54.87
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.60

Is it a good time to buy Zai Lab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zai Lab price performance over time

Historical closes compared with the close of $31.18 from 2025-05-02

1 week (2025-04-25) -2.56%
1 month (2025-04-04) -1.86%
3 months (2025-02-04) 16.47%
6 months (2024-11-04) 0.94%
1 year (2024-05-03) 91.88%
2 years (2023-05-03) -8.21%
3 years (2022-05-03) 39.09
5 years (2020-05-01) 60.42

Zai Lab financials

Revenue TTM $399 million
Gross profit TTM $16.6 million
Return on assets TTM -15.87%
Return on equity TTM -31.41%
Profit margin -64.44%
Book value $7.80
Market Capitalization $3.5 billion

TTM: trailing 12 months

Zai Lab share dividends

We're not expecting Zai Lab to pay a dividend over the next 12 months.

Zai Lab share price volatility

Over the last 12 months, Zai Lab's shares have ranged in value from as little as $16.01 up to $39.77. A popular way to gauge a stock's volatility is its "beta".

ZLAB.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.094. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Zai Lab overview

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc.

Frequently asked questions

What percentage of Zai Lab is owned by insiders or institutions?
Currently 1.433% of Zai Lab shares are held by insiders and 55.551% by institutions.
How many people work for Zai Lab?
Latest data suggests 1,869 work at Zai Lab.
When does the fiscal year end for Zai Lab?
Zai Lab's fiscal year ends in December.
Where is Zai Lab based?
Zai Lab's address is: Jinchuang Plaza, Shanghai, China, 201210
What is Zai Lab's ISIN number?
Zai Lab's international securities identification number is: US98887Q1040
What is Zai Lab's CUSIP number?
Zai Lab's Committee on Uniform Securities Identification Procedures number is: 98887Q104

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

More guides on Finder

Go to site